Edition:
United States

KemPharm Inc (KMPH.OQ)

KMPH.OQ on NASDAQ Stock Exchange Global Market

6.18USD
3:03pm EST
Change (% chg)

$0.88 (+16.51%)
Prev Close
$5.30
Open
$5.35
Day's High
$7.15
Day's Low
$4.65
Volume
316,623
Avg. Vol
11,784
52-wk High
$7.15
52-wk Low
$2.45

Chart for

About

KemPharm, Inc. is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company's product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is... (more)

Overall

Beta: --
Market Cap(Mil.): $77.13
Shares Outstanding(Mil.): 14.66
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 192.73 16.31
EPS (TTM): -- -- --
ROI: -- -0.67 35.74
ROE: -- -3.38 17.71

FDA approves KemPharm's opioid painkiller

KemPharm Inc said on Friday the U.S. Food and Drug Administration approved its opioid painkiller Apadaz for the short-term management of acute pain.

2:13pm EST

BRIEF-Kempharm Announces FDA Approval Of Apadaz

* KEMPHARM SAYS U.S. FDA APPROVED NDA FOR APADAZ FOR SHORT-TERM MANAGEMENT OF ACUTE PAIN SEVERE ENOUGH TO REQUIRE OPIOID ANALGESIC

2:02pm EST

FDA approves KemPharm's opioid painkiller

Feb 23 KemPharm Inc said on Friday the U.S. Food and Drug Administration approved its opioid painkiller Apadaz for the short-term management of acute pain. The company resubmitted the drug's marketing application for review in September last year after appealing against the drug regulator's decision to reject it in 2016.

2:00pm EST

BRIEF-KemPharm posts Q3 loss per share $0.68

* KemPharm reports third quarter 2017 results and provides corporate update

Nov 09 2017

BRIEF-KemPharm receives USAN approval for “asalhydromorphone” as nonproprietary name for novel prodrug candidate, KP511

* KemPharm Inc receives USAN approval for “asalhydromorphone” as nonproprietary name for novel prodrug candidate, KP511 Source text for Eikon: Further company coverage:

Nov 06 2017

BRIEF-KemPharm says KP484 allowed to proceed to clinical studies​

* kempharm’s kp484 for the treatment of adhd, an investigational prodrug of methylphenidate, allowed to proceed to clinical studies

Nov 02 2017

BRIEF-KemPharm files IND application for KP484 for the treatment of ADHD

* KemPharm files IND for KP484 for the treatment of ADHD, an investigational prodrug of methylphenidate

Sep 20 2017

Earnings vs. Estimates